AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 171 min read$AQST

Barber Daniel sold $100K of AQST

Barber Daniel (President and CEO) sold 25,000 shares of Aquestive Therapeutics, Inc. (AQST) at an average of $4.01 ($4.00–$4.03, $0.10M total) across 2 trades over 2026-07-15 to 2026-07-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Barber Daniel
Published Jul 17, 2026, 5:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 17, 2026, 5:23 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$AQST
Neutral
high confidence
Mentioned
$AQST
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AQSTNeutralLow
01

Why it matters

The disclosure updates the record of insider activity, but it does not introduce new company fundamentals. The 10b5-1 plan reduces interpretability as a forward-looking negative signal.

02

Market read

Primarily a sentiment/positioning datapoint for AQST, with limited expected impact absent other catalysts.

03

What to watch

Traders may over-weight the optics of insider selling; without accompanying changes in guidance, trials, or financing, the signal is likely weak.

Relevance 3/10Novelty 3/10Timing: Filed on 2026-07-17, covering sales executed 2026-07-15 to 2026-07-16.

Background

The article is an SEC Form 4 insider transaction for Aquestive Therapeutics, Inc. (AQST) by its President and CEO.

Company-level read

Ticker impact

$AQSTNeutralHigh confidence
Context

Aquestive Therapeutics CEO Barber Daniel sold about $100.2K of AQST shares in two open-market trades under a 10b5-1 plan.

Expected impact

Likely minimal near-term price impact; any reaction would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated 10b5-1 pre-arranged plan, and the article provides no new operational, regulatory, or financial catalyst.

Market effects

Sector

No clear sector read-through; this is company-specific insider trading disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.

Key entities

  • public_company
    AQST

    Aquestive Therapeutics, Inc., issuer of the Form 4 insider sale.

  • insider
    Barber Daniel

    President and CEO who executed the open-market sale under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AQST insider trading history →

Related articles

AUG 19
$AQSTMed

Aquestive (AQST) Q2 2026 Earnings Call Transcript

Aquestive (AQST) reported progress in its Anaphylm resubmission to the FDA, addressing previous issues with packaging and administration. The company's recent studies showed significant improvements in ease of use and effectiveness. Aquestive aims to resubmit Anaphylm before the end of the quarter and believes the product has a strong market opportunity, potentially exceeding $1 billion annually, due to its clinical differentiation and ease of use.

yahoo.com7 min
AUG 12
$AQSTMed

Aquestive Therapeutics Q2 Earnings Call Highlights

Aquestive Therapeutics (NASDAQ:AQST) reported Q2 revenue of $13.8M, up 38% year over year, and a net loss of $22.9M ($0.18/share). Excluding a $11.7M debt-extinguishment loss, net loss was $11.2M. The company discussed FDA resubmission review timing for Anaphylm, cash of $98.5M, and maintained 2026 guidance of $46M to $50M revenue.

yahoo.com7 min
AUG 11
$AQSTMed

Aquestive Therapeutics, Inc. (AQST): Results of Operations and Financial Condition

Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update • Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film • Remains on track to resubmit Anaphyl

SEC EDGAR 8-K4 min
AUG 10
$AQSTMedAI 8/10

Why is Aquestive Therapeutics stock surging today?

Aquestive Therapeutics (AQST) shares rose about 9.4% pre-open after the company reported positive topline results from two pivotal studies for its Anaphylm (dibutepinephrine) sublingual film. The data address FDA concerns from a January 2026 Complete Response Letter and the company said its NDA resubmission remains on track for Q3 2026.

investing.com3 min
AUG 10
$AQSTMed

Aquestive Reports Positive Human Factors and PK Results for Anaphylm, Plans NDA Resubmission Q3 2026

Aquestive Therapeutics (AQST) reported positive human factors and PK topline results for Anaphylm, including faster median pouch open time (17s to 3s) and fewer opening and placement errors. PK Cmax was comparable vs clinician dosing (391.7 vs 357.6 pg/mL) with median Tmax 12 min. No serious adverse events were reported. Aquestive plans to resubmit the NDA in Q3 2026.

tradingview.com1 min